# A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC

> **NCT06424899** · PHASE2 · RECRUITING · sponsor: **Zeng Jian** · enrollment: 92 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Adebrelimab
- **RADIATION:** radical chemoradiotherapy
- **DRUG:** Platinum based chemotherapy

## Key facts

- **NCT ID:** NCT06424899
- **Lead sponsor:** Zeng Jian
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-19
- **Primary completion:** 2027-05-19
- **Final completion:** 2027-12-31
- **Target enrollment:** 92 (ESTIMATED)
- **Last updated:** 2024-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06424899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06424899, "A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06424899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*